Regeneron is expanding its genomics efforts and operations, building upon its strengths in mouse genetics (VelociGene®; VelocImmune® and related technologies) and genetics-driven drug discovery and development (e.g. Interleukin-1 blocker rilonacept, FDA approved in 2008; PCSK9 antibody alirocumab, in Phase 3; and several other important pipeline medicines). Specific capabilities that have been built include large scale whole exome and whole genome sequencing projects, functional biology and mouse genetics for disease modeling, and translational research integrating genetics discovery research with Regeneron's growing pipeline development efforts. Along with others in industry and academia, Regeneron has long seen human genetics and genomics as essential platforms for facilitating and enabling drug discovery and development; we believe technological advances and other trends now make it possible to more fully realize this potential.
Goals for Regeneron's programs include target discovery, indication discovery, and patient-disease stratification through the use of human genetics and related genomic sciences. Regeneron’s interests encompass a breadth of different areas spanning Mendelian and family frameworks, large scale population genetics (both common and rare variants), and gene-gene interactions. The company will rely on its internal assets and technologies as well as continue to collaborate with investigators around the world in pursuing exciting genetics discovery projects. Regeneron has established major collaborations as foundational pieces of its genetics program. Regeneron is looking for talented and motivated individuals to join the company, complement internal teams and resources, and help lead these exciting programs and expanded efforts.
Click here to learn more about the Regeneron Genetics Center from the January 13, 2014 press release.